research use only
Cat.No.: F7112
| Dilution |
|---|
|
| Application |
|---|
| WB, IP, IHC |
| Reactivity |
|---|
| Human, Mouse, Rat, Monkey |
| Source |
|---|
| Rabbit Monoclonal Antibody |
| Storage Buffer |
|---|
| PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3 |
| Storage (from the date of receipt) |
|---|
| -20°C (avoid freeze-thaw cycles), 2 years |
| Predicted MW |
|---|
| 73 kDa |
| Positive Control | Human non-small cell lung carcinoma cells; Human endometrioid adenocarcinoma cells; Human prostate carcinoma cells; HeLa cells; H-4-II-E cells |
|---|---|
| Negative Control |
| WB |
|---|
Experimental Protocol:
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature. 2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min. 3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min. 4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations 2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip"; 4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications Recommended conditions for wet transfer: 200 mA, 120 min. ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight; 2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system. |
| IHC |
|---|
Experimental Protocol:
Deparaffinization/Rehydration
1. Deparaffinize/hydrate sections:
2. Incubate sections in three washes of xylene for 5 min each.
3. Incubate sections in two washes of 100% ethanol for 10 min each.
4. Incubate sections in two washes of 95% ethanol for 10 min each.
5. Wash sections two times in dH2O for 5 min each.
6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
Staining
1. Wash sections in dH2O three times for 5 min each.
2. Incubate sections in 3% hydrogen peroxide for 10 min.
3. Wash sections in dH2O two times for 5 min each.
4. Wash sections in wash buffer for 5 min.
5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
9. Wash sections three times with wash buffer for 5 min each.
10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
12. Immerse slides in dH2O.
13. If desired, counterstain sections with hematoxylin.
14. Wash sections in dH2O two times for 5 min each.
15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
16. Mount sections with coverslips and mounting medium.
|
| Specificity |
|---|
| PRMT5 Antibody [M17F9] detects endogenous levels of total PRMT5 protein. |
| Subcellular Location |
|---|
| Chromosome, Cytoplasm, Golgi apparatus, Nucleus |
| Uniprot ID |
|---|
| O14744 |
| Clone |
|---|
| M17F9 |
| Synonym(s) |
|---|
| Protein arginine N-methyltransferase 5; PRMT5; 72 kDa ICln-binding protein; Jak-binding protein 1; Shk1 kinase-binding protein 1 homolog (SKB1 homolog; SKB1Hs); HRMT1L5; IBP72; JBP1; SKB1 |
| Background |
|---|
| PRMT5 (protein arginine methyltransferase 5) is a type II arginine methyltransferase that forms a stable complex with the methyltransferase cofactor WD repeat domain 77 (WDR77/MEP50) and is widely expressed in mammalian cells, where it catalyzes symmetric dimethylation of arginine residues on histones and multiple non‑histone substrates. PRMT5 is incorporated into chromatin remodeling complexes such as SWI/SNF and NuRD and methylates histones H3 and H4, which modulates chromatin compaction and transcriptional repression at specific loci, including genes involved in differentiation and cell‑cycle control. PRMT5 also methylates RNA‑processing factors and transcriptional regulators, thereby influencing pre‑mRNA splicing, export, and the activity of key signaling effectors, and contributes to the regulation of pathways such as p53‑dependent stress responses, translation initiation via eIF4E, and EGFR/Akt/GSK3β signaling in cancer cells. PRMT5 activity is required for G1‑to‑S phase progression, and loss or inhibition of PRMT5 triggers cell‑cycle arrest and reduces expression of cyclins and other growth‑promoting factors, whereas PRMT5 upregulation or aberrant activity is linked to enhanced proliferation and survival in multiple tumors. PRMT5‑dependent methylation modulates interferon and inflammatory signaling in T cells, and PRMT5 inhibition has been shown to blunt interferon‑stimulated gene expression and STAT1 activation, linking it to immune‑cell activation and inflammatory disease. |
| References |
|---|
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.